Published in Cancer J on August 09, 2010
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 1.36
Recent advances in particulate matter and nanoparticle toxicology: a review of the in vivo and in vitro studies. Biomed Res Int (2013) 1.12
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol (2013) 0.99
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res (2016) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr (2013) 0.88
Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo. J Korean Med Sci (2011) 0.81
Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration. Nucleic Acid Ther (2015) 0.78
Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol (2015) 0.77
CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology (2015) 0.77
Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration. Clin Cancer Res (2017) 0.75
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol (1994) 3.70
CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol (2008) 3.51
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res (2001) 1.82
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol (2007) 1.49
Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol (2009) 1.44
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer (2007) 1.38
Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol (2000) 1.36
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther (1996) 1.24
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res (2001) 1.22
Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol (2006) 1.20
The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res (2001) 1.19
S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology (1993) 1.19
Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res (2003) 1.18
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol (2006) 1.12
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol (2008) 1.11
Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther (2008) 1.11
Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res (2001) 1.10
Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res (2004) 1.09
Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther (2000) 1.04
Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther (2000) 1.04
CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol (2005) 1.03
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res (2007) 1.02
CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol (2007) 1.00
Ectopic lymph nodes within human solid tumors. J Clin Oncol (2008) 0.99
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer (2003) 0.94
Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology (2004) 0.93
Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther (2007) 0.92
Tumor transfected with CCL21 enhanced reactivity and apoptosis resistance of human monocyte-derived dendritic cells. Immunobiology (2007) 0.88
Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol (2006) 0.87
Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol (2005) 0.87
Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther (2004) 0.85
Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther (1999) 0.83
Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother (1993) 0.83
Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J Transl Med (2007) 0.81
Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis. Pathol Int (2004) 0.81
Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med (2003) 0.80
CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biol Ther (2007) 0.78
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res (2006) 2.47
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res (2005) 1.74
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 1.68
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res (2009) 1.43
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 1.36
Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc (2008) 1.31
IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest (2002) 1.29
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol (2008) 1.28
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res (2013) 1.26
COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J (2003) 1.24
Surgical management of endobronchial solitary fibrous tumors. Ann Thorac Surg (2010) 1.23
Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat (2004) 1.22
The role of miRNA in inflammation and autoimmunity. Autoimmun Rev (2013) 1.22
Making room for T cells. J Clin Invest (2002) 1.19
CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci (2004) 1.18
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res (2004) 1.17
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.17
Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther (2007) 1.14
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol (2007) 1.13
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol (2009) 1.12
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol (2006) 1.12
Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics (2011) 1.12
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res (2004) 1.10
Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res (2004) 1.09
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res (2013) 1.07
Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother (2008) 1.04
The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem (2006) 1.04
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother (2008) 1.02
EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol (2007) 1.02
Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother (2006) 1.01
Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays. J Immunol (2003) 1.01
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One (2011) 1.01
The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One (2009) 1.00
Ectopic lymph nodes within human solid tumors. J Clin Oncol (2008) 0.99
Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity. Cancer Immunol Immunother (2010) 0.99
Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol (2004) 0.98
EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol (2003) 0.97
IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol (2003) 0.96
Resection of thyroid cancer metastases to the sternum. J Thorac Oncol (2009) 0.96
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer (2005) 0.95
Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol (2008) 0.95
Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer (2003) 0.94
PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One (2012) 0.94
Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas. J Thorac Oncol (2012) 0.94
Current developments of immunotherapy in the clinic. Curr Opin Immunol (2004) 0.94
Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One (2012) 0.93
PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol (2005) 0.93
PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res (2010) 0.93
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One (2010) 0.93
Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. J Biol Chem (2004) 0.92
IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun (2005) 0.91
Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood (2002) 0.91
Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression. Br J Pharmacol (2014) 0.91
Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res (2003) 0.90
Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant (2006) 0.90
Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J (2003) 0.90
Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res (2006) 0.90
Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun (2002) 0.89
Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res (2011) 0.89
On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother (2003) 0.88
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res (2013) 0.88
Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells. Cancer Immunol Immunother (2005) 0.88
Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin Cancer Res (2002) 0.88
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood (2006) 0.87
Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol (2004) 0.87
A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res (2004) 0.87
The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res (2005) 0.86
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med (2008) 0.86
To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest (2007) 0.86
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res (2004) 0.85
Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther (2004) 0.85
The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. PPAR Res (2008) 0.84
CAR mediates efficient tumor engraftment of mesenchymal type lung cancer cells. Lab Invest (2009) 0.84
Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res (2003) 0.84
Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res (2003) 0.84
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res (2014) 0.84
HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicol Lett (2014) 0.84
IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochem Biophys Res Commun (2006) 0.83
Dendritic cell-based therapeutics for breast cancer. Breast Dis (2004) 0.83